Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products an...
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 8
- Registration Number
- NCT00220727
- Locations
- 🇺🇸
New York Presbyterian Hospital, New York, New York, United States
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00220766
- Locations
- 🇺🇸
The Clinical Trials Center, Children's Hospital, New Orleans, Louisiana, United States
🇺🇸National Jewish Medical and Researach Center, Denver, Colorado, United States
🇺🇸International Center for Interdisciplinary Studies of Immunology, Washington, District of Columbia, United States
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 117
- Registration Number
- NCT00220740
- Locations
- 🇺🇸
Saint Louis University Medical Center, St. Louis, Missouri, United States
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czech Republic
🇵🇱Centre of Clinical Neurology, Neurology Department, Cracow, Poland
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00220805
- Locations
- 🇩🇪
Klininkum der Eberhard-Karls-Universitat Tubingen, Universitats-Augenklinik, Tubingen, Germany
🇩🇪Universitatsklinikum Aachen, Augenklinik, Aachen, Germany
🇩🇪Augenklinik Tausendfensterhaus, Duisburg, Germany
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 128
- Registration Number
- NCT00220779
- Locations
- 🇨🇿
Všeobecná fakultní nemocnice, Prague 2, Czech Republic
🇨🇦Foothills Hospital, Calgary, Alberta, Canada
🇺🇸Neurology Health Care Service, Fletcher Allen Health Care, Burlington, Vermont, United States